Podcasts about Shulman

AS IF we could live without oil! Listen to the full episode on our Patreon (https://www.patreon.com/deniersplaybook) SOCIALS & MORE (https://linktr.ee/deniersplaybook)WANT TO ADVERTISE WITH US? Please contact sponsors@multitude.productionsDISCLAIMER: Some media clips have been edited for length and clarity. CREDITS Created by: Rollie Williams, Nicole Conlan & Ben BoultHosts: Rollie Williams & Nicole ConlanExecutive Producer: Ben Boult Editors: Laura Conte & Paul RamsdellProducers: Daniella Philipson, Irene PlagianosAdditional Research and Fact Checking: Canute HaroldsonMusic: Tony Domenick Art: Jordan Doll Special Thanks: The Civil Liberties Defense CenterSOURCES90magsandmore. (2021). TikTok - Make Your Day. Tiktok.com.Seventeen Magazine, December 1995.ABRAM, L. (2007, March 10). Kingsley, TV reporter, winner of six Emmys. Chron.American Petroleum Institute. (1996, September). Fuel-Less, You Can't Be Cool Without Fuel. Api.org.American Petroleum Institute. (1998). Global-Climate-Science-Communications-Plan-1998. In insideclimatenews.org. American Petroleum Institute.Curtis, R. (2019, February 12). Yesterday. Rotten Tomatoes.Dimmestlmmp. (2017). r/lostmedia. Reddit.com.Fandom. (2025). Make a Wish. DVD Database; Fandom, Inc.Gopal, K. (2024, January 23). A Fossil Fuel Miseducation. The Lever.IMDb. (2025). Nora Stein - Actress. IMDb.Mulvey, K., & Shulman, S. (2015). The Climate Deception Dossiers - Internal Fossil Fuel Industry Memos Reveal Decades of Corporate Disinformation. In ucs.org. Union of Concerned Scientists.Schaeperkoetter, C., Eagle, C., & Oklahoma Energy Resources Board. (2016). Petro Pete's big bad dream. Oklahoma Energy Resources Board.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ailish Forfar and Justin Cuthbert kick off the show with Dan Shulman (0:52) ahead of the Jays' series opener against the White Sox. He shares his thoughts on what's behind the Jays' recent success, the growth of Addison Barger, George Springer's All-Star snub, and much more. Then, Blue Jays legend Jose Bautista joins the show (27:35) to discuss the team's success and what the sweep over the Yankees means to both players and fans alike. They reflect on his experience with a special Blue Jays team and what it is like to be a part of that kind of clubhouse, George Springer's renaissance, taking part in a Home Run Derby, and much more!The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams in-studio to talk about how their ‘no cell phone’ policy has been going this year, the way learning has improved without cell phones in class, how much AI has infiltrated schools, if there […]

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams in-studio to talk about how their ‘no cell phone’ policy has been going this year, the way learning has improved without cell phones in class, how much AI has infiltrated schools, if there […]

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams in-studio to talk about how their ‘no cell phone’ policy has been going this year, the way learning has improved without cell phones in class, how much AI has infiltrated schools, if there […]

In this episode, we dove headfirst into the swirling waters of TypeScript, its real-world use cases, and where it starts to fall short—especially when it comes to security. Joining us from sunny Tel Aviv (and a slightly cooler Portland), we had the brilliant Ariel Shulman and security advocate Liran Tal bring the heat on everything from type safety to runtime vulnerabilities.We started off with a friendly debate: Has TypeScript really taken over the world? Our verdict? Pretty much. Whether it's starter projects, enterprise codebases, or AI-generated snippets, TypeScript has become the de facto standard. But as we quickly found out, that doesn't mean it's perfect.Key Takeaways:-TypeScript ≠ SecurityWe tend to trust TypeScript a bit too much. It's a build-time tool, not a runtime enforcer. As Liran pointed out, “TypeScript is not a security tool,” and treating it like one leads to dangerous assumptions.-Type Juggling is Real (and Sneaky)We explored how something as innocent as using as string on request data can open the door to vulnerabilities like HTTP parameter pollution and prototype pollution. Just because your IDE is happy doesn't mean your runtime is.-Enter Zod – Runtime Type Checking to the Rescue?Zod got some love for bridging the dev-time/runtime gap by validating data on the fly and inferring TypeScript types. But even Zod isn't foolproof. For example, unless you're using .strict(), extra fields can sneak past your validations, leading to mass assignment bugs.-Common Developer FallaciesWe discussed the misplaced confidence developers have in things like code coverage and TypeScript alone. One of the big takeaways: defense in depth matters. Just like testing, layering your security practices (like using Zod, type guards, and proper sanitization) is key.-TypeScript Best Practices Are EvolvingFrom discriminated unions to avoiding any, from using Maps over plain objects to prevent prototype pollution—TypeScript developers are adapting. And tools like modern Node.js now support type stripping, which makes working with .ts files at runtime a bit easier.Become a supporter of this podcast: https://www.spreaker.com/podcast/javascript-jabber--6102064/support.

Ruthie Braffman Shulman is passionate about the importance of women's roles in Torah Leadership positions, and she currently serves as the Director of Women's Torah Leadership at Micah Philanthropies, where she develops and supports women in Torah leadership positions at shuls. Simultaneously, she is the Yoetzet Halacha and community scholar at Young Israel of West Hartford CT.   Ruthie studied at Sha'alvim for Women and Yeshiva University's Stern College and earned an M.A. in Talmud at Yeshiva University's Graduate Program for Advanced Talmudic Studies for Women (GPATS). She is also trained and certified as a Yoetzet Halacha.   Ruthie has nearly twenty years of experience in community leadership and Torah education, having worked at institutions such as United Orthodox Synagogues of Houston, Manhattan Jewish Experience, OU-JLIC at University of Pennsylvania and Drexel University.   She resides in Philadelphia with her husband and four children.   Here is the link to our Survey of Orthodox Jewish Family Life, Marriage & Divorce, available online through June 18, 2025: http://bit.ly/marriage-divorce-2025. 

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about how she managed the school year. Liz tells John about her recent piece in the Wall Street Journal about showing her students ‘The Breakfast Club,’ how the cell phone […]

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about how she managed the school year. Liz tells John about her recent piece in the Wall Street Journal about showing her students ‘The Breakfast Club,’ how the cell phone […]

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about how she managed the school year. Liz tells John about her recent piece in the Wall Street Journal about showing her students ‘The Breakfast Club,’ how the cell phone […]

Derek Shulman in conversation with David Eastaugh https://gentlegiantband.com/ ‘Playing The Fool: The Complete Live Experience', will be released across several formats including double CD, triple vinyl, Blu-Ray and digital download. The album has been remastered and painstakingly remixed from the original source tapes by Dan Bornemark with the Blu Ray containing a stereo 96/24 bit mix, 5.1 surround sound and Dolby Atmos mixes. You can purchase the album here:  https://gentlegiantuk.lnk.to/PTF   Containing new sleeve notes by Alan Kinsman together with a plethora of photographs along with a track list that reflects the original running order of the setlist played on the tour including three previously unreleased songs and the between song banter from Derek Shulman, this represents the most accurate account of Gentle Giant live at the very peak of their powers.   Check out trailer for the album here:  https://youtu.be/f0mqNUE3T6Y   Watch the video for Free Hand here: https://youtu.be/uk_xE116U0Y   Derek Shulman: “Effectively what you're hearing on this album is the whole show with all the bells and whistles included with me speaking to the audience and to the band just like it was on the night.”

Join Justin as he chats with actor Connie Schulman about her childhood in East Tennessee, paranormal experiences with her pets, landing the role of Patti Mayonnaise on Doug, her TV show with Dolly Parton that never aired, and more!Connie Schulman bio:“Constance Ann Shulman (born April 4, 1958) is an American actress. In 1987, Shulman originated the role of Annelle in the first production of Steel Magnoliasoff Broadway. She later appeared in films Fletch Lives (1989), Men Don't Leave (1990), and Fried Green Tomatoes (1991). She voiced Patti Mayonnaise in the animated sitcom Doug (1991–99) and the 1999 film Doug's 1st Movie. She played Yoga Jones in the Netflix comedy-drama series, Orange Is the New Black from 2013 to 2017, for which she received three Screen Actors Guild Award for Outstanding Performance by an Ensemble in a Comedy Series. “Intro and outro theme created by Wyrm. Support Wyrm by visiting the Serpents Sword Records bandcamp page (linked below):https://serpentsswordrecords.bandcamp.com/Monsters, Madness and Magic Official Website. Monsters, Madness and Magic on Linktree.Monsters, Madness and Magic on Instagram.Monsters, Madness and Magic on Facebook.Monsters, Madness and Magic on Twitter.Monsters, Madness and Magic on YouTube

This week, Jeff Gaudiosi and Derek Shulman cover Topics discussed: Gentle Giant Playing The Fool The band's legacy This podcast is hosted by ZenCast.fm

Derek Shulman returns to the podcast to talk about the new Gentle Giant 'Playing The Fool' The Complete Live Experience' Reissue, signing Dream Theater and Pantera, and more.

Derek Shulman was at the heart of two great transformations – Simon Dupree & the Big Sound switching to psychedelia, and then sensing the prog-rock trade winds and becoming Gentle Giant. One minute he was singing Kites, the next Pantagruel's Nativity (Gentle Giant's rebooted ‘Playing The Fool: The Complete Live Experience' is just out). After which he was a record label president signing Bon Jovi, Slipknot and Nickelback and rebooting AC/DC and Bad Company. It's a phenomenal story and involves …   … three pieces of advice for any band today. … playing the ‘64 circuit in his R&B band the Roadrunners. … the fictitious character he invented as Simon Dupree. … when Dudley Moore was their session pianist. … memories of Marc Bolan (“flat on his back playing guitar”), Tony Iommi, Tony Visconti, Don Arden, Gerry Bron and “the English mob”. … what they borrowed from Traffic in the Great Psychedelic Scare of 1967.  … auditioning for George Martin and the lab-coated sound engineers at Abbey Road. … being phoned on a ship returning from Sweden to be told ‘Kites' was Top Twenty and doing Top Of The Pops with Status Quo and the Kinks. … “cars and bags of jewels”: the advantage of being “the darlings of the Isle of Wight Mafia” (which included the Krays). … watching Bowie recording The Man Who Sold The World at Trident. … Elton John's advice that helped form Gentle Giant. … the catastrophic US tour with Black Sabbath (on their “chemical romance”) where the audience threw cherry-bombs onstage: “you learnt how to work a crowd!” … George Underwood's cover for the first Gentle Giant album. … what he saw in Slipknot and why he signed them. You can order GENTLE GIANT – PLAYING THE FOOL: THE COMPLETE LIVE EXPERIENCE here: https://gentlegiantuk.lnk.to/PTFFind out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

Derek Shulman was at the heart of two great transformations – Simon Dupree & the Big Sound switching to psychedelia, and then sensing the prog-rock trade winds and becoming Gentle Giant. One minute he was singing Kites, the next Pantagruel's Nativity (Gentle Giant's rebooted ‘Playing The Fool: The Complete Live Experience' is just out). After which he was a record label president signing Bon Jovi, Slipknot and Nickelback and rebooting AC/DC and Bad Company. It's a phenomenal story and involves …   … three pieces of advice for any band today. … playing the ‘64 circuit in his R&B band the Roadrunners. … the fictitious character he invented as Simon Dupree. … when Dudley Moore was their session pianist. … memories of Marc Bolan (“flat on his back playing guitar”), Tony Iommi, Tony Visconti, Don Arden, Gerry Bron and “the English mob”. … what they borrowed from Traffic in the Great Psychedelic Scare of 1967.  … auditioning for George Martin and the lab-coated sound engineers at Abbey Road. … being phoned on a ship returning from Sweden to be told ‘Kites' was Top Twenty and doing Top Of The Pops with Status Quo and the Kinks. … “cars and bags of jewels”: the advantage of being “the darlings of the Isle of Wight Mafia” (which included the Krays). … watching Bowie recording The Man Who Sold The World at Trident. … Elton John's advice that helped form Gentle Giant. … the catastrophic US tour with Black Sabbath (on their “chemical romance”) where the audience threw cherry-bombs onstage: “you learnt how to work a crowd!” … George Underwood's cover for the first Gentle Giant album. … what he saw in Slipknot and why he signed them. You can order GENTLE GIANT – PLAYING THE FOOL: THE COMPLETE LIVE EXPERIENCE here: https://gentlegiantuk.lnk.to/PTFFind out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

Derek Shulman was at the heart of two great transformations – Simon Dupree & the Big Sound switching to psychedelia, and then sensing the prog-rock trade winds and becoming Gentle Giant. One minute he was singing Kites, the next Pantagruel's Nativity (Gentle Giant's rebooted ‘Playing The Fool: The Complete Live Experience' is just out). After which he was a record label president signing Bon Jovi, Slipknot and Nickelback and rebooting AC/DC and Bad Company. It's a phenomenal story and involves …   … three pieces of advice for any band today. … playing the ‘64 circuit in his R&B band the Roadrunners. … the fictitious character he invented as Simon Dupree. … when Dudley Moore was their session pianist. … memories of Marc Bolan (“flat on his back playing guitar”), Tony Iommi, Tony Visconti, Don Arden, Gerry Bron and “the English mob”. … what they borrowed from Traffic in the Great Psychedelic Scare of 1967.  … auditioning for George Martin and the lab-coated sound engineers at Abbey Road. … being phoned on a ship returning from Sweden to be told ‘Kites' was Top Twenty and doing Top Of The Pops with Status Quo and the Kinks. … “cars and bags of jewels”: the advantage of being “the darlings of the Isle of Wight Mafia” (which included the Krays). … watching Bowie recording The Man Who Sold The World at Trident. … Elton John's advice that helped form Gentle Giant. … the catastrophic US tour with Black Sabbath (on their “chemical romance”) where the audience threw cherry-bombs onstage: “you learnt how to work a crowd!” … George Underwood's cover for the first Gentle Giant album. … what he saw in Slipknot and why he signed them. You can order GENTLE GIANT – PLAYING THE FOOL: THE COMPLETE LIVE EXPERIENCE here: https://gentlegiantuk.lnk.to/PTFFind out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

In this episode, we speak with Derek Shulman, founding member and multi-instrumentalist of the legendary 70's prog rock band Gentle Giant.  We discuss the band's career and the re-release of their 1977 groundbreaking live album, Playing The Fool.

Derek Shulman and John Weathers never looked back, and maybe that's why Gentle Giant's music still stares you The post Gentle Giant's Derek Shulman and John Weathers appeared first on The Strange Brew .

Dr. John Sweetenham, Dr. Larry Shulman, and Dr. Rebecca Maniago discuss the integration of clinical pathways and decision support tools into the cancer center workflow, challenges to implementation at the point of care, and the promise of AI to further unlock these tools for clinicians. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. Over the last decade or so, there has been a great deal of work and a lot of discussion about the implementation of oncology clinical care pathways at the point of care, which are designed to reduce variability in care, reduce costs, and improve the quality of care and outcomes. Although clinical pathways aim to guide treatment decisions, current data suggests that the utilization of these pathways at the point of care is very low. There are many reasons for this, which we will get into on the episode today.   My guests today are Dr. Larry Shulman and Rebecca Maniago. Dr. Shulman is a professor of medicine at the University of Pennsylvania Abramson Cancer Center. He's also the immediate past chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academies of Sciences, Engineering and Medicine. Rebecca Maniago is the director of clinical oncology at Flatiron Health, a technology platform that collects and analyzes real-world clinical data from electronic health records to facilitate decision making and research.  Our full disclosures are available in the transcript of this episode. Larry and Rebecca, welcome to the ASCO Daily News Podcast and many thanks for being here.  Dr. Larry Shulman: Thank you, John.  Rebecca Maniago: Thank you for having me.  Dr. John Sweetenham: Larry, I'm going to start out, if I may, with a question for you. You and I, in a previous podcast, have discussed some of these issues regarding pathway implementation before. But to start out with, it's certainly, I think, helpful for the listeners to remind us all of what are the benefits of oncology clinical pathways and why are we still talking about this 10 years or more on.  Dr. Larry Shulman: Yeah, and that's a great question, John. I think the good news is, and all of us who live in the oncology sphere know this, that there's been tremendous progress in cancer therapies over the last decade. But what that has entailed is the introduction of many new therapies. Their complexity is becoming really very tough for people to manage.  And so what we have are oncologists who are really trying to do their best to deliver care to patients that will give them the best chance for survival and quality of life. But it's really, really hard to keep up with everything that's happening in oncology in the context of what we all know is a very busy clinic schedule. Lots of patients coming through and decisions need to be made quickly. Pathways really could help us to guide us into recommending and delivering the best therapies for our patients for a particular disease. You know, cancer is complicated. There are many different types and there are many different therapies. It's just a lot to deal with without some assistance from pathways or pathway tools.  Dr. John Sweetenham: Thanks, Larry. So, knowing that's the case and knowing that these tools reduce variability, improve costs, improve quality of care as well. Starting with you again, Larry, if I may, why do you think it's been so difficult for so many oncologists to use these pathways effectively at the point of care?  Dr. Larry Shulman: So, I just wanted to step back a little bit. There are very extensive guidelines that tell us what the best therapies are for really all of the cancers. These guidelines come from the National Comprehensive Cancer Network or NCCN and the American Society of Clinical Oncology or ASCO and other professional organizations. And they're there. They're there, in free information off their websites.  But the problem is how to translate those pretty dense documents into something that will work in the clinic for a patient, for the physician who's working in the electronic health record. And the tools that are available, and there are a number of tools that can integrate with electronic health records, are expensive. You need to purchase them from the vendor and there are yearly fees.  And they're also difficult to implement. You need to work with the vendor to integrate them into your own rendition of your electronic health record. And there's a lot of customization that needs to be done. So, it's a financial challenge and it's also a time challenge for people to integrate these tools into their workflow, into their electronic health records.  Dr. John Sweetenham: Thanks, Larry. So speaking from my own past experience of pathway implementation, it certainly has been a major challenge for the reasons that you mentioned and also because of the, I think resistance may or may not be too strong a word, of many of the clinicians to use these for a number of reasons, part of which are the time it takes, part of which many of them feel that the pathways aren't really changing decisions that they might make anyway. So, you know, the uptake of pathway utilization, even in those centers which have been successful in getting something installed and plugged into their EHR, on the whole, hasn't been as good as it could have been. So maybe I'll turn to you, Rebecca, because I know that this is something that you've worked on a lot.  And it's a kind of double-barreled question. I think the first part of it is, you know, what do you think are the major roadblocks to high physician uptake in the use of these pathways platforms? And maybe you could talk a little bit about what the various software platforms do to make them more physician-friendly and to enhance utilization right on the front line.  Dr. Rebecca Maniago: Yeah, that's a great question. And so, you know, I've worked with a number of customers and physicians over the past five and a half years on implementing these pathways. And the number one pushback is really about the time it takes in the workflow. So, if I had a dollar for every time I heard “every click counts,” I'd be a rich person and it does come down to clicks. And so, you know, as a software vendor, we really have to focus on how do we reduce that friction?  How do we make sure that the clicks we are asking for are the ones that actually matter? And how do we continue to streamline that process? And so, you know, while there is a fine balance, because as part of a Pathways platform, at the end of the day, we do need to understand some data about that patient. You need to understand the clinical scenario so you can surface the right treatment recommendation, which means there is some amount of data capture that has to happen. In some circumstances, you know, we can pull some of that data in from the EHR.  But unfortunately, the reality is that a lot of that data is messy and it's sort of stuck in documents and unstructured places. And so it doesn't easily flow in, which means we rely on the provider to give us that information. And oftentimes they've already entered it other places. So what's more frustrating than entering data twice? But, you know, I do see a great opportunity here. And this is certainly where software companies are focused is with AI.  So, know, for, especially for this data aggregation, a lot of these AI tools can actually scan through the chart instead of relying on the physician to sort of manually skim through and aggregate and find all that pertinent information. That's what AI is really good at. And almost instantaneously, it can find the messy data that lives in those unstructured documents. And wouldn't it be nice if that was automatically populated within these applications so that really all we're asking of the clinician is to validate that that information is accurate. And then choose the treatment that cuts down on the number of clicks, it cuts down on frustration. You know, again, the physician will be the one that needs to make that decision. AI is not there to replace that, but it certainly has a great opportunity to reduce some of this manual documentation and the things that physicians find the most frustrating, especially as it relates to using these pathways tools.  Dr. John Sweetenham: One of the pretty common pushbacks that I heard during my time in a couple of institutions was, “Well, you know, I'm sitting here at the point of care with my patients and I already know what I want to do and how I'm going to treat that patient if it's not in the context of a clinical trial. So I don't need to go through, you know, X number of clicks to get me to where I know I'm going to be anyway.”  Does either of you have any thoughts about that? I think you've sort of partially answered it, but what do you think, Rebecca? Do you think that this is something that is more easily overcome-able, if that's even a word, than it was a few years back?  Rebecca Maniago: Yeah, I do. And I think this is where the customization comes into play. So while they may know what an appropriate treatment for their patient is, there are more options now than ever, which means at a local level, there may be multiple options that are clinically equivalent. And so when you think about things like payer pathways or drug margins as an organization, they have to drive some of that from within. But having the capability to do so can then start to sort of sell the value to the provider that, yes, you may know what you want to order for your patient, but would you consider something else if it was clinically equivalent, but it had other benefits to either the patient or the organization?  Dr. Larry Shulman: The other thing I would add to that, John, if I can jump in here is that the data is the data and the data shows us that guideline concordant care is not always prescribed to the US. And in fact, in some circumstances, the gaps between what should be prescribed and what is being prescribed are quite wide. So, you know, people feel like they're always doing the best job and making the best recommendations. And I think, you know, I think I am. But, you know, like many of my colleagues at academic cancer centers, I'm highly specialized. I only see patients with breast cancer. But many oncologists throughout the country are more generalists. They're seeing patients with multiple diseases. And it's harder for them to be completely on top of what the current recommendations are in any particular circumstance. Our diseases are complicated. They're getting more complicated all the time with molecular and genomic testing and subcategorizations of different cancers. So, I don't think that we can be too cocky about it, quite frankly. I think we ought to use technology that Rebecca describes for the tools and for AI to really help us. I think if we turn our backs on that, I think we're making a big mistake. You just got to look at the data. The data is pretty convincing.  Dr. John Sweetenham: You know ever since we started looking seriously at decision support through pathways a number of years ago, the word has always been around the payers role in this and the day will come where we are going to get reimbursed based on pathway and concordance and I'm not sure that that day has arrived. So I have a question for both of you in this regard actually. And the first of those is maybe I'll start with you for this part of it, Larry. Where do you think we are in that regard? And are you hearing more and more of payers starting to look at pathway compliance? And then on the other end of that, and maybe I'll ask Rebecca about this, is one of the other pushback issues that I used to experience from physicians I worked with was they may go through the pathways platform and come up with a treatment recommendation. The best example of this I can think might be that the recommendation might be a biosimilar. Let's just use that as an example. But the next stage in the process would be to find out whether the patient's insurance would actually cover that particular biosimilar, which opened up a whole new can of worms. So there are two kinds of payer aspects of that. Maybe Larry, I'll ask you to start off by talking about that kind of coverage issue. And then I'll ask Rebecca, if you have any thoughts about the flow the other way in terms of getting drugs approved and what we can do to help from an insurance perspective.  Dr. Larry Shulman: Sure, that's really an important point, John. Our current state of affairs with the payers and their attempt to be sure that we're providing responsible, guideline concordant care is the use of prior authorization processes, which are incredibly costly, both for the oncology practices and for the payers.  They have an army of nurses sitting at the phone talking to us in the oncology practices to decide whether they're going to pay for something. And frankly, generally, the payers will pay for things that are part of either the NCCN or ASCO or other professional organizations' guidelines. But you need to prove to them over the phone that in fact the patient qualifies for that.  We have actually had some experiments with some of the payers to prove that to them in different ways by auto transmission of data. And this would be a big savings for them and for us, it would take away some of the delays in therapy while we're waiting for prior authorizations to go through. And we shouldn't have to do this by phone.   The EHR and the pathway tools should aggregate the data, aggregate the potential treatment and be able to transmit those data to the payer. And if in fact it meets the appropriate criteria for guideline concordant care would be approved. Right now, it's a terrible, costly, timely manual process that they should be able to fix.  Dr. John Sweetenham: Thanks, Larry. And have you, you know, from a broader perspective, so not thinking necessarily about individual patients and specific issues around prior authorization, have you seen any movement among the payers to kind of get more aggressive about this and say, okay, you know, we are going to want to see your numbers, we want to know how many of your physicians are now using their pathways platform and so on. Are you seeing any word that that might be happening? Because certainly a few years back, that was the word on the street, as it were, that this day was coming.  Dr. Lawrence Shulman: And that's the proposal that we've made to several of our payers. Let us give you the aggregate data. If our guideline concordance is above a certain level, give us a gold card, give us a pass, and we won't need to do pre-authorizations. We've actually done that at my institution in radiology. Aggregate data gives individual physicians that pass if their guideline concordance was appropriate. I got to pass. So I don't need to go through those radiology pre-authorizations for my patients. And I think we can do the same thing with therapeutics. It's been a little bit more cumbersome to do it, and there's some detailed reasons why that is. But that's really what they want to know. And the payers want to know that patients are getting guideline concordant care, but they also realize it's not going be 100%. There are always a few outlier patients who require some variation from the guidelines. But if we get above 80% guideline concordant care, I think many of the payers would be happy to accept that as long as we continue to feed them the data. And that's the case in our radiology process with one of the payers is, you know, I get a gold card, but they continue to look at my data. And if I don't continue to perform well, they'll take that away.  Dr. John Sweetenham: Thanks, Larry. And Rebecca, just returning to you, this issue of prior authorization and facilitating life for the physician at the point of care in terms of knowing, you know, which specific treatment might be covered for a patient. Do you have any thoughts or maybe you could give us some insights on what software vendors are doing to facilitate that part of the process, the communication back to the payers to take some of that burden off the physician and the physician staff?  Rebecca Maniago: Yeah, absolutely. And this is a problem we've been trying to tackle for years. And it's not easy. We've tackled it in a couple ways. So first, we try to sort of link up to the payer portal where the information that was being attested to within the application could then be automatically sent. Because at the end of the day, the data points that are being collected to surface treatment recommendations ultimately are the same data points that the payer wants.  Unfortunately, there are a lot of data interoperability challenges within that space. So that was not something that was going to be sustainable. However, in current state, because as I mentioned, the customization is key for these products, focusing more on how can we allow practices to embed payer pathways within the application. So again, you kind of start with the backbone of your standard guidelines but then having the capability of adding in a payer pathway that will only show up as that preferred option for a patient who has that insurance, at least at the point of care, the provider sees what the insurer would then approve. So while it's not automatically assuring authorization, we are at least steering the decision in a direction where we think most likely this is going to be approved based upon the pathway that they have access to. So that sort of current state, I agree. We've been talking about this idea of gold carding for years.  Presumably the data is there today, right? Like we are able to capture structured data with every order placed to recognize concordance to Larry's point. All those reports are available to provide to payers. I just haven't seen a lot of practices have a lot of success when they tackle it on their own from that direction.  Dr. John Sweetenham: Right, thanks. Larry, you and I were at the NCCN annual meeting recently and I know that you've been quite heavily involved in the policy program and in the policy forums and so on at NCCN. Are you able to share anything from this year's meeting in terms of care pathways implementation and what you think might happen next in that regard?  Dr. Larry Shulman: NCCN, in my own opinion, has really led the way in defining what guideline concordant care is through their guidelines, which are very extensive, covering basically every cancer and every situation with every cancer. And it's really an astounding amount of amazing work that all of us use and the payers largely use as well. But they've increasingly understood that there's a gap between their guidelines and the implementation of their guidelines. And they are working on some things. They are working on the digitalization of their guidelines to make them more accessible, but also thinking about ways that they may, in fact, fit into the work processes that all of us have when we go to clinic.  They're acutely aware that the country is not where it needs to be in regard to a translation, if you will, of their guidelines in the practice. And I think we're all thinking really hard about whether there are things that we can team up to do, if you will, to try to close those gaps.  Dr. John Sweetenham: Great, thank you. Just switching gears a little bit back to you, if I can, Rebecca. I think you've said a little bit about this already. What do you think are the next steps that we need to take to more effectively implement these tools in the clinic? I think we've discussed a little bit some of the roadblocks to that. But where do you think we need to go next in terms of getting better use of these pathways?  Rebecca Maniago: Yeah, I will say one thing that we haven't really touched on is the pharmacy team. So the biggest blocker that I see is actually the pre-implementation. So there's a lot of focus on how do we get physicians to use this? How do we increase adoption? But often the first barrier is the regimen library. So no matter what the pathways platform is, the backbone of it will be those regimens. And so, really helping organizations and we partner with pharmacies, they're doing all the backend configuration. And so how can we make that piece of the technology easier for them to implement because that's really the lead up and there's a ton of cleanup and maintenance. You know, as a pharmacist, I empathize, but really that's where it all begins. And so I think, you know, continuing to focus on not only the front end user and the physician, but everybody that's going to be involved in order to make a pathway program successful needs to be, you know, at the table in the beginning, helping set up those processes and, and buying into the why this is important.  Dr. John Sweetenham: That's a great point.  Dr. Larry Shulman: So could I just jump in one quickly here, John? So pathways, as we've discussed, the tools are expensive. There is a person cost, as Rebecca is just describing, about customization and implementation. But there are very good data in the literature to show that when you follow pathways, care is less costly. Survival is better, which is obviously our primary goal, but also cost is less. And the payers can benefit from that. And the question is, can they figure out ways to use that to help to fund the purchase and maintenance of pathway products that will give their patients better care, but also less costly care? And so I think that is a potential solution. I've had that conversation with some payers as well. And it would be great to see that happen. I think that would be a huge step.  Rebecca Maniago: Yeah, we have some, if they're able to set it up in the right way and really optimize, you know, from the pharmacy perspective, we have practices who the application is more than, you know, paying for itself just by way of using it to the fullest potential that it has.  Dr. John Sweetenham: Yeah, that's a really great point. A couple of other more general questions. I'm going to start with you, Rebecca, and Larry ask you to respond as well. Are you hearing anything from patients around this issue? Are they aware or becoming more aware that pathways are being used in the clinic when they're seen by their physicians? And do they have a say, are there patient advocates involved in this part of the process? Rebecca, maybe you could start.  Rebecca Maniago: I haven't had as much exposure to that side of it. So, you know, I would love to hear what Larry thinks because most of my exposure is at the physician level, which of course they are the ones who are making the decision with the patient. So my assumption is that there is at least some level of understanding that there are options and that, you know, together let's decide on the best one for you. But again, I would love to hear what Larry has to say.  Dr. Larry Shulman: Yeah, so that's a really interesting question. I actually was discussing that at the cancer center last week, particularly around the utilization of AI in this process. And, you know, right now, as you know, if you submit a journal article or, you know, many other things, ask you whether you used AI to generate it. If in fact we use tools that include AI, we're not.  Are we obligated to tell the patient that you're making this recommendation together with computer assist, if you will, that helps you to make the recommendation you are making to them? Ultimately, I think it's the physician who's responsible for the choice, but should we disclose it? I have to tell you personally, I haven't thought about doing that. But I think it's a really, really good question is whether we should upfront tell the patients that we've had assistance in making the recommendations that we have.  Dr. John Sweetenham: Right, very interesting point. To close it out, one more question for both of you and again, it's the same one. Rebecca, to start with, we've all been, as I said right up front, talking and, you know, working on this issue for more than 10 years now. In 10 years from now, how would you like it to look and how do you think it might look?  Rebecca Maniago: Great question. I think we may get to where I would like to see it quicker than 10 years. I think AI provides a lot of opportunity and excitement. I'd love to turn a corner where physicians no longer see tools like this as a hindrance, rather they rely on them, they trust them, they help them get through their day. They continue to improve quality of care and reduce costs and patient burden. Obviously, that's the pipe dream, but I think we may get there before 10 years, given what I think AI is going to enable.  Dr. Larry Shulman: Yeah, I want to add to Rebecca's comments. One of the things that I worry about, and ASCO worries about a lot, is the oncology workforce, which is progressively strained in their attempts to care for all the cancer patients in the US. And for all of us who practice oncology, for many reasons, it's become more and more inefficient, whether it's use of the EHR, pre-authorization work, and so on.  And we really need to turn that around. We need to make practice not only better, which I think these tools can do, including AI, as Rebecca says, but make it much more efficient because that's going to allow us to both deliver more high-quality care to our patients, but also to care for more patients and have them benefit from our expertise and what we have to offer. So I think this is really an obligation on our part. I think it's an imperative that we move in this direction for both quality reasons and efficiency reasons.  Dr. John Sweetenham: Thanks, Larry. Well, I've really enjoyed the conversation today and I think, you know, it's been great to think about some of the challenges that we still have in this regard. But it's also great to hear what I'm sensing is quite a lot of optimism about how things may play out over the next few years. And it does sound as if there's a lot of hard work going on to bring us to a point where the clinical decision support tools are going to truly support what our oncologists are doing and no longer be seen as an obstruction. So, I want to thank you both for sharing your insights with us today on the ASCO Daily News Podcast.  Dr. Larry Shulman: Thank you so much, John.  Rebecca Maniago: Thank you so much.  Dr. John Sweetenham: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. John Sweetenham  Dr. Lawrence Shulman  Rebecca Maniago  Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose    Dr. Lawrence Shulman:  Consulting or Advisory Role: Genetech     Rebecca Maniago:   No relationships to disclose.     

Divorce is complicated. Having to go through the process of getting a lawyer and splitting assets can be a challenge. But what if you and your partner own a business together? That's where things can get complicated. Laura Paris, associate lawyer at Shulman & Partners LLP, joins us to take us through on what happens to your business when you are going through a divorce. Find out more at shulman.ca and connect on Instagram, X/Twitter and Facebook.

A personal finance book for teenagers. Shannon Lee Simmons, certified financial planner, chartered investment manager, life coach and author, takes us through Making Bank: Money Skills for Real Life.  Then, the financial cost of ignoring burnout. Olga Morawcynski, founder of Heal-3 and a mental wellbeing advocate, tells us about her journey.  And, how joint business ownership can complicate a divorce. Laura Paris, family lawyer with Shulman & Partners, takes us through the process.  Plus, we speak with Juan Sebastian D'Achiardi, of TransUnion Canada, about its TruVision Trended Risk Score. To find out more about the guests check out: Shannon Lee Simmons: Shanno Lee Simmons(IG) | New School of Finance(IG) Juan Sebastian D'Achiardi: LinkedIn | Instagram Heal-3: heal-3.com | LinkedIn Olga Morawcynski: LinkedIn Laura Paris: shulman.ca | Instagram | X/Twitter | Facebook Bruce Sellery is a personal finance expert and best-selling author. As the founder of Moolala and the CEO of Credit Canada, Bruce is on a mission to help you get a better handle on your money so you can live the life you want. High energy & low B.S., this is Moolala: Money Made Simple. Find Bruce Sellery at Moolala.ca | Twitter | Facebook | LinkedIn

Send us a textWelcome to another insightful episode of Business Growth Talks with Mark Hayward. This week, our guest is sales guru Eric Shulman, the brains behind Truth Based Selling—a methodology designed to enhance sales conversations with honesty and client-focused clarity. During the episode, Eric shares his rich journey from a music store family business to becoming a towering figure in the world of sales training. His foundational belief is that authentic communication and truthful interactions are pivotal in making sales processes more effective and building lasting client relationships.In this episode, Eric Shulman digs into the realities of scaling a business and the pivotal role of sales in this journey. Through SEO-focused insights, Eric explains how entrepreneurs can harness the power of effective communication and authentic client interaction in sales strategies. The conversation touches on essential concepts like diagnosing before prescribing, nurturing client relationships, and the importance of knowing when to pivot in business ventures. Eric's innovative ideas challenge traditional sales norms and advocate for strategies that make sales a client-centric, ethical process. Listen to Eric as he shares compelling anecdotes and actionable advice that promise to enrich your business acumen.Key Takeaways:Truth Based Selling emphasizes genuine communication and problem-solving over aggressive sales tactics, making interactions more client-focused and less adversarial.Diagnosing before prescribing is critical; understanding a potential client's needs and challenges should always precede offering solutions.Embrace entrepreneurial spirit by betting on oneself and pivoting when necessary, which can turn ideas into successful business ventures.Communication psychology plays a significant role in sales. Understanding behavioral cues and emotional triggers can enhance how sales professionals engage with potential clients.Legacy in sales involves positively impacting clients' lives by ethically helping them solve their problems, thereby creating long-lasting professional relationships.Resources:Eric Shulman's Website: Consultants Can SellSandler Training: Sandler TrainingBook Reference: "Games People Play" by Dr. Eric BerneListeners are encouraged to tune into this content-rich episode to glean actionable insights tailored for anyone passionate about elevating their sales strategy or business. Stay connected for more episodes featuring transformative discussions with seasoned industry experts.Support the showIf you want to watch the full video of this episode go to:https://www.youtube.com/@markhayward-BizGrowthTalksDo you want to be a guest on multiple podcasts as a service go to:www.podcastintroduction.comFind more details about the podcast and my coaching business on:www.businessgrowthtalks.comFind me onLinkedIn - https://www.linkedin.com/in/mark-hayw...Tik Tok - https://www.tiktok.com/@mjh169183YouTube Shorts - https://www.youtube.com/@markhayward-BizGrowthTalks/shorts

Mikey Shulman is having a great time. He's running a rocket ship of a company, has $100M+ in funding from some of the top VCs, and is working on an opportunity that he's passionate about. Mikey hit my radar because of a text from my friend TJ. His firm was an early backer of Suno, and he said that if any company they work with was going to hit our “4 Min Mile” challenge of $100M in revenue with fewer than 10 employees, it'd be Suno. That was the conversation I was planning to have with Mikey when we stepped into the studio at Suno HQ in Cambridge. What unfolded was a conversation with much more nuance and range than I'd originally anticipated. Some takeaways:Mikey emphasizes the importance of fun in AI development, contrasting with the industry's focus on productivity gains. He sees AI as a tool for enhancing human creativity in music, potentially leading to new heights in artistic expression.Shulman sees AI as a tool that, like humans, learns from past data to create new expressions. He disagrees with the notion that AI can only look backward, arguing that it can be a powerful instrument for innovation in music when guided by human creativity.The company's rapid growth was aided by staying somewhat removed from the AI hype cycle, allowing them to focus on building value and iterating quickly based on user feedback.Despite raising significant capital, Shulman actively tries to avoid fixating on the company's war chest. He believes constantly thinking about available funds can distort decision-making and lead to inefficient resource allocation.Shulman credits much of Suno's success to his talent for hiring and building a strong team, rather than his own ideas. He stresses the value of finding people who are passionate and committed to the company's mission.As Suno approaches the $100M mark with a much bigger team than 10, I can't help but wonder if there's more indie can be doing to encourage and support founders who are thinking similarly about small teams with ambitions for massive scale. We're doing that already through our direct investing, but I wonder if there's a program we could put together that would involve investment and shared learnings from a group of like-minded founders working towards a similar goal that could help the whole get there that much quicker. If you have thoughts on this, please share. It's something we're actively thinking through, and I would value additional ideas and points of view. As always, we hope you enjoy watching this one as much as we enjoyed recording it. If you're working on something with a similar ethos to Suno and looking for investment, don't hesitate to reach out. — Bryce

The Mark Moses Show is joined by Head Basketball Coach Jeremy Shulman of UT-Martin to recap his first year on campus, what he learned from his time coaching at Eastern Florida State College and his thoughts on the NCAA Tournament heading into Sweet 16 Matchups later this week in the world of College Basketball.  Mark is also joined by Tim Walters of The Florida Today to talk about his career, his love for sports on the Space Coast and his picks for Match Madness kicking off this week in the world of College Basketball.  Mark broadcasts from the Anidjar & Lavine Accident Attorneys Studio.    #Podcast #MosesShow #Basketball, MarchMadness #Interview 

As we prepare for a future traveling the stars, energy-efficient processing technologies will be a necessity for both those in space and those remaining as Earth's stewards. Holly Shulman, research professor at Alfred University, shares how she became interested in microwave sintering, describes its benefits compared to conventional sintering processes, and explains how it could support the development of future lunar colonies.View the transcript for this episode here.About the guestHolly Shulman is research professor at Alfred University and founder, president, and chief technology officer of Bluestar Advanced Manufacturing. She specializes in developing microwave processing technologies, and she was recently named director of the new Space Materials Institute at Alfred University in part due to the potential applications of her research on the moon. She will be giving a talk on microwave processing for lunar construction at the 59th Annual Microwave Power Symposium in June 2025, and she plans to teach an ACerS short course in the near future.About ACerSFounded in 1898, The American Ceramic Society is the leading professional membership organization for scientists, engineers, researchers, manufacturers, plant personnel, educators, and students working with ceramics and related materials.

Fund manager Dr. Joel Shulman is bringing private equity access to retail investors. Meet XOVR, the exchange-traded fund that includes private holdings like SpaceX—typically only available to big institutions or cashed-up individuals. Hear how deferred IPOs have made private equity a $13 trillion market, and why Dr. Shulman believes there’s still massive growth potential, even dwarfing cryptocurrency. Discover the risks and advantages of XOVR, the unique entrepreneurial index it tracks, and the implications of including private assets that trade much more slowly. Plus, how do Elon’s recent controversies impact XOVR’s substantial SpaceX holdings? For more or to watch on YouTube—check out http://linktr.ee/sharedlunch Shared Lunch is brought to you by Sharesies Limited (NZ) in New Zealand and Sharesies Australia Limited (ABN 94 648 811 830; AFSL 529893) (collectively referred to as ‘Sharesies’). Appearance on Shared Lunch is not an endorsement by Sharesies of the views of the presenters, guests, or the entities they represent. Their views are their own. Shared Lunch is not personal financial advice and provides general information only. We recommend talking to a licensed financial adviser. You should review relevant product disclosure documents before deciding to invest. Investing involves risk. You might lose the money you start with. Content is current at the time.See omnystudio.com/listener for privacy information.

John Shulman is the Founder and President of Alignor, a negotiation expert with Harvard credentials, and a consultant to business leaders worldwide. This episode is all about the art of negotiation—from handling tough procurement conversations to defending price in a world of price-focused buyers.Learn about the interest-based negotiation approach, where it aligns (or conflicts) with today's high-stakes sales environment, and how AI is reshaping the way we negotiate. If you are looking for sharpen your negotiation skills and close better deals real with world strategies and insights, this episode is a must-listen.Are you interested in leveling up your sales skills and staying relevant in today's AI-driven landscape? Visit www.jbarrows.com and let's Make It Happen together!Connect with John on LinkedIn: https://www.linkedin.com/in/johnbarrows/Connect with John on IG: https://www.instagram.com/johnmbarrows/Check out John's Membership: https://go.jbarrows.com/pages/individual-membership?ref=3edab1 Join John's Newsletter: https://www.jbarrows.com/newsletterConnect with John Shulman on LinkedIn: https://www.linkedin.com/in/john-shulman-1b12202/?Check out John Shulman's Website: https://www.alignor.com/

Shulman v. Collins

In this episode of Daily Influence, host Gregg-Brooke Koleno sits down with Joyce Shulman—coach, author, and business igniter—who helps women navigate the intersection of personal and professional growth. Joyce shares insights from her entrepreneurial journey, from launching businesses in consumer products and media to creating impactful wellness brands.She introduces her 10 Touch Strategy, a powerful framework for fostering meaningful relationships and business success. Together, they explore the importance of integrating work and life, overcoming time constraints, and prioritizing relationships with intention. Joyce also reveals her own journey in setting boundaries and making time for personal joy—proving that business is personal.Join us for a conversation on leadership, connection, and the small, consistent actions that create a lasting impact. Tune in now and start embracing influence with purpose!

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about the state of public education under the Trump administration, her thoughts on JB Pritzker wanting classrooms to be ‘screen free,’ and the impact of AI and other technology on […]

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about the state of public education under the Trump administration, her thoughts on JB Pritzker wanting classrooms to be ‘screen-free,’ and the impact of AI and other technology on students.

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about the state of public education under the Trump administration, her thoughts on JB Pritzker wanting classrooms to be ‘screen-free,’ and the impact of AI and other technology on students.

Mikey Shulman, Co-Founder and CEO of Suno, comes back on the podcast to answer your questions from X with Lightspeed Partner Michael Mignano. Mikey shares about Suno's growth over the past year, introducing new models, and launching their mobile app. They also address numerous questions from the audience about the potential of AI in creating realistic music, copyright issues, and the future vision for AI-generated compositions. Episode Chapters00:00 Introduction and Guest Welcome01:09 Suno's Recent Developments01:45 Mobile App and User Experience02:01 AI Music Models and Quality05:06 Community Questions and API Discussion06:43 Future of AI in Music12:14 Copyright and Legal Considerations14:24 Challenges and Opportunities in AI Music23:17 Open Source AI Models26:54 Future Enhancements and User Controls29:50 Collaborative Music Creation31:42 AI Voice Enhancement33:12 Future of Music Videos34:20 User Demographics and Live Jamming36:09 Multimodal Inputs and Personalization38:47 Blockchain and Music41:29 AI's Sense of Taste in Music44:37 Social Music and Prompting Tricks48:41 Educational Features and Future Vision52:02 Building an AI Startup58:32 Conclusion and Final ThoughtsStay in touch: www.lsvp.com X: https://twitter.com/lightspeedvp LinkedIn: https://www.linkedin.com/company/lightspeed-venture-partners/ Instagram: https://www.instagram.com/lightspeedventurepartners/ Subscribe on your favorite podcast app: generativenow.co Email: generativenow@lsvp.comThe content here does not constitute tax, legal, business or investment advice or an offer to provide such advice, should not be construed as advocating the purchase or sale of any security or investment or a recommendation of any company, and is not an offer, or solicitation of an offer, for the purchase or sale of any security or investment product. For more details please see lsvp.com/legal.

Elon Musk, a corporate billionaire and private naturalized American citizen born in South Africa, has taken an extraordinary amount of power in government since Donald Trump took office as President less than a month ago. Musk is seeking to interfere with elections in Germany and other countries around the world. Vance recently told European leaders to allow more “free speech” but what that means is use of social media and media to push authoritarianism. Dr. Stuart Shulman holds a PhD in American Politics and has done extensive teaching and leadership roles in collaborative interdisciplinary research. Additionally, as founder and CEO of Texifter, he discussed the analysis of Twitter data, his work supporting academic access to data, and federal agency review of public comments on proposed rules. Stuart and I discussed how Twitter was gamified through QAnon since 2017. He tracked QAnon, a tale of a high-up government official with a “Q-level” clearance covering nuclear weapons and related materials and tweeting about supposed confidential information. Coded language and “crumbs” were then created to entice signaling, and Trump often alluded to this through tweets. Stuart noted that in a December 1-12, 2017, dataset with 2.3 million mentions of Michael Flynn, “#followthewhiterabbit” and “the Great Awakening” and other QAnon buzzwords in the Tweets. Stuart noted how the Alternate Reality Gaming (ARG) characters often have made-up names and emojis and could have come from anywhere in the world, including Russia, China, India, and other nations that may not have the best interests of voters and citizens in western democracies. Learn more about your ad choices. Visit megaphone.fm/adchoices

The videos and images of recent airplane crashes are hard to shake.  For some, it has ignited a fear of flying – but is it warranted?The statistics say one thing, but our minds say another.  So what can we do?  Host Melanie Ng speaks with Dr. Ian Shulman, Psychologist and Clinical Director at Shift Cognitive Therapy - where even her subconscious kicks in, making an error right at the beginning of the episode, contrary to her notes!  You can learn more about Dr. Shulman at https://shiftct.com/.   We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Jeremy Shulman is in his first season leading UT Martin and has the Seahawks in the mix in the OVC. He spent the last 14 seasons at Eastern Florida State College. He chatted with Ian Sacks and Isaac Bourne about his first impressions of Division I basketball.

This weekend's 1 in 36 guest is Gary Shulman. Gary was the Program Director of Social Services, Training Coordinator and Special Camp Fair Coordinator for Resources for Children with Special Needs, Inc. for over 24 years. He has now transitioned to the role of consultant/trainer on a private basis. Gary is also a published poet. He also serves as a volunteer Advisory Commissioner in Arlington, VA. Tune in to learn more about the virtual workshops he provides nationally, or visit: https://garyshulman.jimdo.com

Mikey Shulman is the Co-Founder and CEO of Suno, the leading music AI company. Suno lets everyone make and share music. Mikey has raised over $125M for the company from the likes of Lightspeed, Founder Collective and Nat Friedman and Daniel Gross. Prior to founding Suno, Mikey was the first machine learning engineer and head of machine learning at Kensho technologies, which was acquired by S&P Global for over $500 million.  In Today's Episode with Mikey Shulman: 1. The Future of Models:  Who wins the future of models? Anthropic, OpenAI or X? Will we live in a world of many smaller models? When does it make sense for specialised vs generalised models? Does Mikey believe we will continue to see the benefits of scaling laws? 2. The Future of UI and Consumer Apps:  Why does Mikey believe that OpenAI did AI consumer companies a massive disservice? Why does Mikey believe consumers will not choose their model or pay for a superior model in the future?  Why does Mikey believe that good taste is more important than good skills? Why does Mikey argue physicists and economists make the best ML engineers? 3. The Future of Music:  What is going on with Suno's lawsuit against some of the biggest labels in music? How does Mikey see the future of music discovery? How does Mikey see the battle between Spotify and YouTube playing out? How does Mikey see the battle between TikTok and Spotify playing out?  

The Lawyer Stories Podcast Episode 210 features Cary London, Managing Partner at Shulman and Hill in Greater New York City focusing on Civil Rights, Police Brutality, Excessive Force, Wrongful Convictions, and Personal Injury.  Cary is the Chair of the Civil Rights Division of the Brooklyn Bar Association, and a Board Member of the Brooklyn Defender Services.  Cary is also a Founding Member of Lawyer Stories Connect!  Cary's journey as a civil rights lawyer began during his tenure as a Public Defender in Brooklyn. Cary witnessed, firsthand, the systemic injustices prevalent in the criminal justice system. This experience ignited a fire within him to advocate for change and pursue justice for those who have been marginalized or wronged.  One case at a time, Cary is becoming a voice for those in need, consistently striving to create a more equitable society for all.

Check out Tory's weekly show Daytime After Dark on YouTubeFollow Tory on IG: @iamtoryshulmanFollow the show on IG: @didthatagewell TikTok: @didthatagewellpodWatch this episode this episode on YouTube and subscribe to the channel! youtube.com/@didthatagewellEmail: didthatagewell@gmail.com

Love, Norm: Inspiration of a Jewish American Fighter Pilot (Modern Jewish History) by Norman M. Shulman Amazon.com Lovenormmemoir.com Norm Shulman's relationship with his stepson Greg Levenson had always been stable and warm, but it altered when Greg decided to enlist in the Air Force at age 27. This unexpected decision brought them even closer together, and Norm came to realize that his whole family history had much support to offer Greg. Cognizant of past anti-Semitic stereotypes persisting about Jewish participation in the military, Norm wanted to help prepare Greg to feel comfortable in his own identity. So, Norm decided to write letters that connected Greg to the many Jewish military heroes who had preceded him. From Judah Maccabee to fighter pilots from today's recent history, these profiles in courage and heroism brought Greg foundation and strength, and they offer readers a breadth of knowledge from every corner of Jewish history. Norm's letters to Greg make up one core of Love, Norm; the other is Norm's own multigenerational story of Jewish military heroes. As the son of Jewish immigrants whose place in America was hard-won, Norm chronicles what it was like to feel his identity pulled in different directions and how to hold fast to it nonetheless. Love, Norm is a multifaceted retelling of inspirational profiles of famous Jewish fighters from across history, and it is also the singular story of how one man dug into his own past and found pieces to preserve his Jewish identity. Together, empathetically channeled through his heartfelt letters and remembrances, Love, Norm shares a collected wisdom with the next generation.

Jonathan Shulman, Senior Partner at McKinsey & Company, highlights the transformative potential of AI in the software industry and the evolutions needed to capture emerging market opportunities.Topics Include:AI's transformative potential in the software industry.Why AI is a massive business opportunity.Software industry evolution: Mainframe to Cloud SaaS eras.Potential entrance into a new AI-driven era.AI spend forecast: $15B to $200B by 2026.Most AI spend repurposed from existing IT budgets.Legacy software spend likely shifting towards AI.Importance of targeting specific, high-impact AI use cases.Key areas disrupted: sales, marketing, software engineering.AI's adoption rates vary by industry and function.Four waves of AI: predictive to agent-based.Most companies are still in early AI stages.Prioritize building agentic, end-to-end AI solutions.Winning companies invest disproportionately in AI innovation.Position offerings to tap into AI-specific budgets.Deliver complete workflows, not isolated point solutions.Generative AI accelerates development and iteration cycles.Scaling AI pilots remains a major industry challenge.Tool fragmentation undermines productivity and innovation.Change management critical for successful AI integration.Rethinking team roles and processes for AI deployment.Consumption-based pricing models gaining industry traction.Shift from perpetual to subscription to consumption models.Balancing value-driven and cost-efficient consumption pricing.AI market poised to redefine IT and business landscapes.Participants:Jonathan Shulman – Senior Partner, McKinsey and CompanySee how Amazon Web Services gives you the freedom to migrate, innovate, and scale your software company at https://aws.amazon/isv/

On November 2, 2016, thirty-four-year-old so-called “Supermom” Sherri Papini went out for a run near her home in Redding, California, and disappeared without a trace. Three weeks later, on Thanksgiving Day, Sherri was discovered on the side of the road in a nearby county, where she said her captors had released her. In the days that followed, Sherri claimed she had been kidnapped by two unknown Latin American women, who physically abused her, including branding her on the shoulder with the word “Exodus.” The case garnered considerable attention from the local and national media, but when it came to details on her abductors and their motives, Sherri was surprisingly tight-lipped, giving the police and FBI little to work with. In March 2022, more than five years after her supposed abduction, the nation was shocked to learn that federal agents had arrested Papini and charged her with faking her own kidnapping. A month later, Sherri pleaded guilty to the charges and was sentenced to more than a year in prison. The news was stunning and left everyone wondering, why would a seemingly ordinary and ostensibly happy mother orchestrate such a bizarre hoax?Thank you to the Incredible Dave White of Bring Me the Axe Podcast for research and Writing support!ReferencesABC News. 2016. "Missing California mom found alive after captor abandons her in restraints, sheriff says." ABC News, November 24.Ayestas, Jonathan. 2024. "Sherri Papini has yet to pay $300,000 fine for faked 2016 California kidnapping." CNN Newswire, March 26.Bella, Timothy. 2022. "A mother said she was kidnapped. Now she admits it was all a hoax." Washington Post, April 13.Bever, Lindsey, and Kristine Guerra. 2016. "Missing California mother found alive three weeks after her apparent abduction, police say." Washington Post, November 25.Bonvillian, Crystal. 2022. "Feds detail how missing mom branded, starved self in 2016 kidnapping hoax." Cox Media Group, March 9.CBS News, Sacramento. 2016. "Full text of November 30 press conference about Sherri Papini's abduction." CBS News, Sacramento, November 30.Federal Bureau of Investigation. 2022. Sherri Papini criminal complaint and affidavit. Criminal complaint, Los Angeles, CA: Federal Bureau of Investigation.Gumbel, Andrew. 2022. "California jogger Sherri Papini staged own violent kidnapping, FBI says." The Guardian, March 4.—. 2016. "Kidnapping, reverse ransom and a bounty: the strange case of Sherri Papini." The Guardian, December 30.Hurley, Beven. 2022. "Why did it take five years to charge 'supermom' Sherri Papini with fabricating her own abduction?" The Independent, March 4.Larimer, Sarah. 2016. "California mother was 'branded' and covered in bruises after apparent abduction, husband says." Washington Post, November 29.Longoria, Sean. 2016. "Mother of 2 goes missing near Redding." Record Searchlight (Redding, CA), November 4: 1.—. 2016. "Audio tells of Papini response." Record Searchlight, November 27: 1.Sabalow, Ryan. 2016. "Familty of 'supermom' holds on to hope." Sacramento Bee, November 12: 1.—. 2016. "Keep an open mind in unusual kidnap story, experts say." Sacramento Bee, December 3: B1.—. 2016. "Relative defends husband of missing 'supermom'." Sacramento Bee, November 9: A14.—. 2017. "Sheriff's office silent on Papini details." Sacramento Bee, January 31.—. 2016. "'Supermom' hasn't been seen since taking a jog." Sacramento Bee, November 8: A4.Sandhu, Amber. 2016. "Missing mom sought." Record Searchlight (Redding, CA), November 5: 1.Serna, Joseph. 2016. "A setback in kidnapping case?" Los Angeles Times, December 1: B3.Shulman, Alayna. 2016. "Sherriff gets help in search." Record Searchlight, November 8: 1.—. 2017. "Will 2018 bring more Papini details?" Record Searchlight, December 28: 6.Solis, Nathan. 2022. "Tale of abduction by Latinas fueled racial unease." Los Angeles Times, March 6: B2.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We're joined by TV personality Tory Shulman to discuss the complexities of grief, resilience, and finding humor even in the darkest moments.  + ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow our new Instagram account⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Head ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for all things Angel Aesthetics ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠It Hurts To Be Pretty on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Angel Aesthetics on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find us on TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Shop Skincare & Merch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ What would you like to hear on the podcast? Write us at podcast@skincarebyangel.com

Full show - FrYiday | Hillbilly hookup | News or Nope - Winter drinking and Celine Dion | Tajin souvenir | Telephone talent show | Slacker wants his parking spot vengeance | Tory Shulman is filling in for Erin today | Who gets to name the baby? | Women love men with scars | Sexy voices | Stupid stories @theslackershow @thackiswack @radioerin

Erin is on vacation in London, so our friend Tory Shulman is filling in. Don't worry - Erin will be back on Monday!